Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Vir Biotechnology Inc VIR

Healthcare Biotechnology
Vir Biotechnology, Inc. is an immunology company, which is focused on combining cutting-edge technologies to treat and prevent serious infectious diseases and other serious conditions. The Company's clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). It also has several preclinical... see more

Recent & Breaking News (NDAQ:VIR)

Vir Biotechnology Scientists Named Winners of the BARDA and HHS-Sponsored Pediatric COVID-19 Data Challenge

GlobeNewswire April 6, 2022

Vir Biotechnology to Participate in the 21st Annual Needham Healthcare Conference

GlobeNewswire April 4, 2022

Camden Property Trust Set to Join S&P 500; Matador Resources to Join S&P MidCap 400; Vir Biotechnology to Join S&P SmallCap 600

PR Newswire March 29, 2022

US Food and Drug Administration Revises Emergency Use Authorization for Sotrovimab Due to Omicron BA.2 Subvariant

GlobeNewswire March 25, 2022

Vir Biotechnology to Participate in the 42nd Annual Cowen Healthcare Conference

GlobeNewswire March 2, 2022

Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2021 Financial Results

GlobeNewswire February 24, 2022

Vir Biotechnology to Provide Corporate Update and Report Fourth Quarter and Full Year 2021 Financial Results on February 24, 2022

GlobeNewswire February 10, 2022

2 Stocks Winning Their Battles Against COVID Today

Stockhouse Editorial February 10, 2022

Data Suggest Sotrovimab Retains Neutralizing Activity Against Omicron Subvariant BA.2

GlobeNewswire February 10, 2022

Vir Biotechnology Appoints Johanna Friedl-Naderer as Executive Vice President and Chief Business Officer, Global

GlobeNewswire February 8, 2022

Vir Biotechnology Launches New Antibody Research Initiative Aimed at a Functional Cure for HIV and Prevention of Malaria

GlobeNewswire January 13, 2022

GSK and Vir Submit Emergency Use Authorization Application to FDA for Intramuscular Administration of Sotrovimab for the Early Treatment of COVID-19

GlobeNewswire January 13, 2022

GSK and Vir Biotechnology Announce United States Government Agreement to Purchase Additional Supply of Sotrovimab, Authorized for the Early Treatment of COVID-19

GlobeNewswire January 11, 2022

Vir Biotechnology to Present at 40th Annual J.P. Morgan Healthcare Conference

GlobeNewswire January 4, 2022

Vir Biotechnology Announces New Research Describing the Structural Basis of SARS-CoV-2 Omicron Immune Evasion and Receptor Engagement

GlobeNewswire December 31, 2021

Xevudy (Sotrovimab) Granted Marketing Authorization by the European Commission for the Early Treatment of COVID-19

GlobeNewswire December 17, 2021

Preclinical Data Highlight the Significant Antigenic Shift of the Omicron SARS-CoV-2 Variant and its Effect on the Neutralizing Activity of Monoclonal Antibodies, Convalescent Antibodies and Vaccine-Elicited Antibodies

GlobeNewswire December 14, 2021

Vir Biotechnology Announces Initiation of Phase 2 Clinical Trial Evaluating VIR-2218, Selgantolimod and Nivolumab for the Treatment of Chronic Hepatitis B Virus Infection

GlobeNewswire December 9, 2021

Vir Biotechnology to Host a Call on Sotrovimab's Retained Activity Against the Omicron SARS-CoV-2 Variant

GlobeNewswire December 7, 2021

Preclinical Studies Demonstrate Sotrovimab Retains Activity Against the Full Combination of Mutations in the Spike Protein of the Omicron SARS-CoV-2 Variant

GlobeNewswire December 7, 2021